Researchers at the Massachusetts Institute of Technology (MIT) develop a new strategy in Cambridge (United States)
Arthritis joints and cartilage into the cartilage joints. Beforehand, it is tested in rats and is a breakthrough in the treatment of the progression of this disease, which has no cure.
Arthrosis is a progressive degeneration of the cartilage of the joints due to aging or lesions. This pathology affects about 300 million people around the world and does not reverse, as it is a cartilage, it can not be rebuilt. Accordingly, patients may have an impact on the prosthesis of the affected joint affected or continue to undergo pharmacological treatment, but this is the opposite
it is very difficult to get into the cartilage.
Most drugs have been removed from the joints before they have an effect or can not penetrate into the cartilage, cells that produce it – conditionals – so they can not fulfill their function.
Researchers led by the MIT sought a strategy to overcome this obstacle. They designed a nano-maker that acts as a vehicle for accessing a molecule
cartilage inside and take a medication to concoctions. It forms a spherical component that binds this molecule, and thus connects the drug to the branch structure, with a positive electric charge and the PEG compound.
Since the cartilage is a negative charge, the positive charge of the nanocaric acid retains the fabric. PEG, however, breaks through the cartilage and reaches condrocytes.
According to the newspaper La Vanguardia, it receives a journal publication
Science Translational Medicine, Scientists added a drug called IGF-1 to stimulate nuclease, cartilage production and survival and condrosis growth.
To test the strategy, the drugs were injected with nano-carriers, after an injury to the arthritis's knee joints. The treatment reduced the appearance of cartilage degeneration, inflammation and osteoarthritis. Regarding the IGF-1 injection, the combination of nanokaras only multiplied by the average ten-drug drug. In addition, effective cartilage concentrations have been maintained within thirty days, and therefore, for two months or more, one injection would be sufficient.